SMAD2 and glioblastoma: Our findings reveal that TEFT inhibits the TGF‐β/SMAD2/3/STAT3 signaling pathway, which subsequently downregulates C1R expression, ultimately suppressing EMT and reducing the aggressive mesenchymal phenotype of GBM.